This webinar by Pablo Lopez, Sweden and Gitte Moos Knudsen, Denmark, was recorded on 21 February 2025 as part of the ‘A European perspective on psychedelics research, from pharmacology to clinical effects’ webinar series, organised by the ECNP Psychedelic Research Network.
Building on the foundation provided in the first session, a closer look is taken at the preclinical and clinical research investigating the mechanism of action of psychedelics. The talk shows how animal models and neuroimaging can be used to advance our knowledge on how psychedelics interact with the brain to create beneficial effects.
About the ‘A European perspective on psychedelics research, from pharmacology to clinical effects’ webinar series
In this webinar series, the wide scope of psychedelics research conducted at various centers in Europe is explored. Throughout three sessions, a wide range of topics is covered: from pharmacology and preclinical investigations to the clinical trials conducted in psychiatry. The sessions in this series build upon each other but can also be viewed in isolation. In each session, cutting-edge research is presented by esteemed researchers from different universities in Europe.
First session: Clinical pharmacology of psychedelics and insights from the limited medical use program in Switzerland
This is the second session in the series.
Third session: Clinical applications in psychedelics; current evidence from meta-analysis and experiences from Sweden
Views and opinions expressed in these videos are those of the presenters and do not necessarily reflect the official position of ECNP. The content of these videos should not be used in any way as the basis for treatment decisions.
